|
|
轻度Graves眼病防治的现状与展望
|
Abstract:
Graves眼病(Graves’ophthalmopathy, GO)，也称为甲状腺眼病或甲状腺相关眼病，是Graves病(Graves disease, GD)的主要甲状腺外表现。因为存在严重不良反应的潜在风险，目前大多数可用的药物都用于治疗中度至重度Graves眼病的患者，通常不推荐用于治疗轻度甲状腺眼病。对于轻度甲状腺眼病，治疗的选择有限，主要包括观察随访和局部治疗，本文将对轻度Graves眼病的预防及治疗作一概述。
Graves’ ophthalmopathy (GO), also known as thyroid ophthalmopathy or thyroid-associated ophthalmopathy, is the main extrathyroidal manifestation of Graves’ disease (GD). Because of the potential risk of serious adverse effects, most of the currently available drugs are used to treat patients with moderate to severe Graves’ ophthalmopathy and are generally not recommended for the treatment of mild thyroid eye disease. The treatment options for mild thyroid ophthalmopathy are limited, mainly including observation, follow-up and local treatment. This article will review the prevention and treatment of mild Graves ophthalmopathy.
| [1] | Luigi, B., et al. (2021) The 2021 European Group on Graves’ Orbitopathy (EUGOGO) Clinical Practice Guidelines for the Medical Management of Graves’ Orbitopathy. European Journal of Endocrinology, 185, G43-G67. |
| [2] | 陈灏珠, 林果为. 实用内科学[M]. 第16版. 北京: 人民卫生出版社, 2022: 1933. |
| [3] | Ma, C., Li, H., Lu, S. and Li, X. (2024) Thyroid-associated Ophthalmopathy: The Role of Oxidative Stress. Frontiers in Endocrinology, 15, Article 1400869. https://doi.org/10.3389/fendo.2024.1400869 |
| [4] | Ippolito, S., Cusini, C., Lasalvia, P., Gianfagna, F., Veronesi, G., Gallo, D., et al. (2020) Change in Newly Diagnosed Graves’ Disease Phenotype between the Twentieth and the Twenty-First Centuries: Meta-Analysis and Meta-Regression. Journal of Endocrinological Investigation, 44, 1707-1718. https://doi.org/10.1007/s40618-020-01479-z |
| [5] | Le Moli, R., Naselli, A., Giudice, F.L., Costanzo, G., Frasca, F. and Belfiore, A. (2024) Temporal Trends in the Clinical Presentation of Graves’ Orbitopathy: A Single-Center Retrospective Study. Journal of Endocrinological Investigation, 47, 2177-2184. https://doi.org/10.1007/s40618-024-02332-3 |
| [6] | Ozturk, M., Konuk, O., Tarlan, B., Yalcın, M.M., Arıbas, Y.K., Toruner, F.B., et al. (2022) Clinical Characteristics and the Treatment Modalities of Graves’ Orbitopathy in a Tertiary Referral Center in Turkey: Changes over Two Decades. International Ophthalmology, 43, 643-653. https://doi.org/10.1007/s10792-022-02468-2 |
| [7] | Menconi, F., Profilo, M.A., Leo, M., Sisti, E., Altea, M.A., Rocchi, R., et al. (2014) Spontaneous Improvement of Untreated Mild Graves’ Ophthalmopathy: Rundle’s Curve Revisited. Thyroid, 24, 60-66. https://doi.org/10.1089/thy.2013.0240 |
| [8] | Thornton, J., Kelly, S.P., Harrison, R.A. and Edwards, R. (2006) Cigarette Smoking and Thyroid Eye Disease: A Systematic Review. Eye, 21, 1135-1145. https://doi.org/10.1038/sj.eye.6702603 |
| [9] | Shahida, B., Planck, T., Singh, T., Åsman, P. and Lantz, M. (2024) Smoking Enhances Proliferation, Inflammatory Markers, and Immunoglobulins in Peripheral Blood Mononuclear Cells from Graves’ Patients. Endocrine Connections, 13, e230374. https://doi.org/10.1530/ec-23-0374 |
| [10] | Oeverhaus, M., Winkler, L., Stähr, K., Daser, A., Bechrakis, N., Stöhr, M., et al. (2023) Influence of Biological Sex, Age and Smoking on Graves’ Orbitopathy—A Ten-Year Tertiary Referral Center Analysis. Frontiers in Endocrinology, 14, Article 1160172. https://doi.org/10.3389/fendo.2023.1160172 |
| [11] | Ye, X.Z., Huang, S.S., Liu, J., Lu, B. and Shao, J.Q. (2019) High Serum Cholesterol: A Novel Risk Factor for Thyroid Associated Ophthalmopathy? Chinese Journal of Internal Medicine, 58, 823-825. |
| [12] | Nilsson, A., Tsoumani, K. and Planck, T. (2021) Statins Decrease the Risk of Orbitopathy in Newly Diagnosed Patients with Graves Disease. The Journal of Clinical Endocrinology & Metabolism, 106, 1325-1332. https://doi.org/10.1210/clinem/dgab070 |
| [13] | Rosetti, S., Tanda, M.L., Veronesi, G., Masiello, E., Premoli, P., Gallo, D., et al. (2019) Oral Steroid Prophylaxis for Graves’ Orbitopathy after Radioactive Iodine Treatment for Graves’ Disease Is Not Only Effective, but Also Safe. Journal of Endocrinological Investigation, 43, 381-383. https://doi.org/10.1007/s40618-019-01126-2 |
| [14] | Vannucchi, G., Covelli, D., Campi, I., Currò, N., Dazzi, D., Rodari, M., et al. (2019) Prevention of Orbitopathy by Oral or Intravenous Steroid Prophylaxis in Short Duration Graves’ Disease Patients Undergoing Radioiodine Ablation: A Prospective Randomized Control Trial Study. Thyroid, 29, 1828-1833. https://doi.org/10.1089/thy.2019.0150 |
| [15] | Ponto, K.A., Binder, H., Diana, T., Matheis, N., Otto, A.F., Pitz, S., et al. (2015) Prevalence, Phenotype, and Psychosocial Well-Being in Euthyroid/hypothyroid Thyroid-Associated Orbitopathy. Thyroid, 25, 942-948. https://doi.org/10.1089/thy.2015.0031 |
| [16] | Humayun, S.K., Uzma, M., Farooq, A., et al. (2021) Conservative Management of Thyroid Eye Disease. Journal of the College of Physicians and Surgeons—Pakistan, 30, 599-601. |
| [17] | Li, D. and Sun, F. (2021) Observations on the Efficacy of Two Methods for the Treatment of Upper Eyelid Retraction in Thyroid-Associated Ophthalmopathy. BioMed Research International, 2021, Article ID: 9514279. https://doi.org/10.1155/2021/9514279 |
| [18] | Marcocci, C., et al. (2011) Selenium and the Course of Mild Graves’ Orbitopathy. The New England Journal of Medicine, 364, 1920-1931. |
| [19] | Almanza-Monterrubio, M., Garnica-Hayashi, L., Dávila-Camargo, A. and Nava-Castañeda, Á. (2021) Oral Selenium Improved the Disease Activity in Patients with Mild Graves’ Orbitopathy. Journal Français d’Ophtalmologie, 44, 643-651. https://doi.org/10.1016/j.jfo.2020.08.029 |
| [20] | Yuan, P., Xi, Y.C., Jian, Z., et al. (2022) Doxycycline vs Placebo at 12 Weeks in Patients with Mild Thyroid-Associated Ophthalmopathy: A Randomized Clinical Trial. JAMA Ophthalmology, 140, 1076-1083. |
| [21] | Matoc, I., Kasa, K., Kasumović, A., Prpić, A., Vukojević, A., Zrinšćak, O., et al. (2024) One Incremental Stride for Doxycycline, One Substantial Advancement for Thyroid Eye Disease. Diagnostics, 14, Article 791. https://doi.org/10.3390/diagnostics14080791 |
| [22] | 汪艳美. 云克联合激素冲击治疗Graves眼病的疗效观察[D]: [硕士学位论文]. 恩施: 湖北民族大学, 2019. |
| [23] | Heisel, C.J., Riddering, A.L., Andrews, C.A. and Kahana, A. (2020) Serum Vitamin D Deficiency Is an Independent Risk Factor for Thyroid Eye Disease. Ophthalmic Plastic & Reconstructive Surgery, 36, 17-20. https://doi.org/10.1097/iop.0000000000001437 |
| [24] | 宋静静. 维生素D辅助治疗轻度Graves眼病的临床疗效[D]: [硕士学位论文]. 济宁: 济宁医学院, 2024. |
| [25] | Zawadzka-Starczewska, K., Stasiak, B., Wojciechowska-Durczyńska, K., Lewiński, A. and Stasiak, M. (2022) Novel Insight into Non-Genetic Risk Factors of Graves’ Orbitopathy. International Journal of Environmental Research and Public Health, 19, Article 16941. https://doi.org/10.3390/ijerph192416941 |
| [26] | Moshkelgosha, S., Verhasselt, H.L., Masetti, G., Covelli, D., Biscarini, F., Horstmann, M., et al. (2021) Modulating Gut Microbiota in a Mouse Model of Graves’ Orbitopathy and Its Impact on Induced Disease. Microbiome, 9, Article No. 45. https://doi.org/10.1186/s40168-020-00952-4 |
| [27] | Filippo, B., Giulia, M., Ilaria, M., et al. (2023) Gut Microbiome Associated with Graves’ Disease and Graves’ Orbitopathy: The IN-DIGO Multi-Centre European Study. The Journal of Clinical Endocrinology and Metabolism, 108, 2065-2077. |
| [28] | Hou, J., Tang, Y., Chen, Y. and Chen, D. (2021) The Role of the Microbiota in Graves’ Disease and Graves’ Orbitopathy. Frontiers in Cellular and Infection Microbiology, 11, Article 739707. https://doi.org/10.3389/fcimb.2021.739707 |
| [29] | 何志伟, 胡欣, 陈国芳, 等. 抗氧化剂: 治疗甲状腺相关性眼病的新选择[J]. 眼科新进展, 2022, 42(5): 417-420. |
| [30] | Ataabadi, G., Dabbaghmanesh, M.H., Owji, N., Bakhshayeshkaram, M. and Montazeri-Najafabady, N. (2020) Clinical Features of Graves’ Ophthalmopathy and Impact of Enalapril on the Course of Mild Graves’ Ophthalmopathy: A Pilot Study. Endocrine, Metabolic & Immune Disorders—Drug Targets, 20, 139-148. https://doi.org/10.2174/1389201020666190725113816 |
| [31] | Xu, Z., Ye, H., Xiao, W., Sun, A., Yang, S., Zhang, T., et al. (2022) Metformin Attenuates Inflammation and Fibrosis in Thyroid-Associated Ophthalmopathy. International Journal of Molecular Sciences, 23, Article 15508. https://doi.org/10.3390/ijms232415508 |
| [32] | Bartalena, L., Gallo, D., Tanda, M.L. and Kahaly, G.J. (2023) Thyroid Eye Disease: Epidemiology, Natural History, and Risk Factors. Ophthalmic Plastic & Reconstructive Surgery, 39, S2-S8. https://doi.org/10.1097/iop.0000000000002467 |
| [33] | Burch, H.B., Perros, P., Bednarczuk, T., Cooper, D.S., Dolman, P.J., Leung, A.M., et al. (2022) Management of Thyroid Eye Disease: A Consensus Statement by the American Thyroid Association and the European Thyroid Association. European Thyroid Journal, 11, e220189. https://doi.org/10.1530/etj-22-0189 |
